This event is not part of the official Scientific Sessions Conference 2024 as planned by the AHA Committee on Scientific Sessions Programming.

Saturday, November 16, 2024

6:00 PM CT - 6:15 PM CT – Registration & Dinner
6:15 PM CT – 7:15 PM CT – CE Symposium

Hilton Chicago Hotel
720 South Michigan Avenue
Chicago, IL 60605
Meeting Room: Salon A1 -A2, Lower Level

PROGRAM FEATURES

• • Downloadable whiteboard animation
  • Interactive case-based presentation
  • Create-your-own personalized poster

	Karl Doghramji, MD, FAASM, DFAPA Professor of Psychiatry and Human Behavior Thomas Jefferson University Jefferson Sleep Disorders Center Philadelphia, PA
	Nancy Foldvary-Schaefer, DO, MS Professor of Neurology, Cleveland Clinic Lerner College of Medicine Sleep Disorders and Epilepsy Centers Neurological Institute Cleveland Clinic Cleveland, OH

PROGRAM OVERVIEW

Welcome to an enlightening satellite symposium dedicated to elevating the knowledge and skill set of cardiologists in managing patients with idiopathic hypersomnia (IH) and narcolepsy. As vital members of the multidisciplinary team (MDT), cardiologists play a crucial role in addressing the unique challenges presented by these sleep disorders. This symposium specifically aims to enrich your understanding of the cardiovascular risks associated with IH and narcolepsy, empowering you to implement evidence-based treatment strategies that prioritize patient safety and well-being.

The education will seek to help HCPs better assess the burden of IH and narcolepsy, including the major cardiovascular risks comorbid with IH and narcolepsy; summarize the importance of limiting sodium intake to manage cardiovascular risk in patients with IH and narcolepsy, including through use of lower-sodium oxybate; and justify the importance of a multidisciplinary shared decision-making approach in patients with IH and narcolepsy to ensure optimal clinical management.

 LEARNING OBJECTIVES 

After completing the CME activity, learners should be better able to: 

• Assess the burden of IH and narcolepsy, including the major cardiovascular risks comorbid with these conditions.
• Summarize the importance of limiting sodium intake to manage cardiovascular risk in patients with IH and narcolepsy, including through use of lower-sodium oxybate.
• Justify the importance of a multidisciplinary shared decision-making approach in patients with IH and narcolepsy to ensure optimal clinical management.

TARGET AUDIENCE 

This educational activity is designed to meet the needs of cardiologists, who are an essential part of the multidisciplinary team (MDT) of specialists managing idiopathic hypersomnia and narcolepsy.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of up to 1.0 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT 

Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc).  Please contact Med Learning Group prior to the live event at info@medlearninggroup.com